bioRxivCancer Biology
Exploring Degradation of Intrinsically Disordered Protein YAP induced by PROTACs
Abstract
Yes-associated protein (YAP), a potent oncogene and a key player in the Hippo tumor suppression pathway, has long been considered challenging to target due to its partially intrinsically disordered nature. However, recent advances in High-throughput Screening (HTS) have led to the discovery of a few YAP binders. Building upon this progress, a novel approach utilizing Proteolysis-Targeting Chimera (PROTAC) technology was employed to design and synthesize a series of YAP degraders. Here, our degraders were created by linking NSC682769, a previously reported YAP binder, with either VHL ligand 2 or pomalidomide using various linkers of different lengths and types. The most promising degrader YZ-6 recruits the E3 ligase VHL, inducing rapid and sustained YAP degradation leading to suppression of YAP/TEAD-led transcription in both YAP-dependent NCI-H226 and Huh7 cancer cell lines. In addition to its degradation capabilities, YZ-6 also exhibited potent antiproliferative activity in both cell lines. Importantly, YZ-6 efficiently suppresses tumor development in the Huh7 xenograft mouse model without adverse effects on the mice. These findings highlight the potential of PROTAC-mediated degradation as a viable strategy for reducing oncogenic YAP levels and attenuating downstream signaling in cancer cells. Moreover, the development of PROTACs based on NSC672869 holds promise for treating YAP-driven malignancies.
- organism: human
- assay: proteomics
- research focus: drug response / drug discovery
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Cooperatively Designed Aptamer-PROTACs for Spatioselective Degradation of Nucleocytoplasmic Shuttling Protein for Enhanced Combinational Therapy
- Development of a Novel PROTAC using the Nucleic Acid Aptamer as a Targeting Ligand for Tumor Selective Degradation of Nucleolin
- Development of LYTACs via incorporating a nucleolin-targeting and lysosome-directed aptamer
Fang Qiu, Ziting Feng, … Chao Liang·bioRxiv·Aug 29, 2025
- ESCRT-dependent YAP degradation by AKT blockade overcomes adaptive resistance to RAS(ON) inhibition in pancreatobiliary cancer
Jack W. Sample, Enis Özmert, … Rory L. Smoot·bioRxiv·Oct 20, 2026
- Degradation of intrinsically disordered proteins using proteolysis targeting nanobody conjugate
Xiaofeng Sun, Dinglan Wu, … Xi Chen·bioRxiv·Nov 27, 2024
- Allosteric Modulation of YAP/TAZ-TEAD Interaction by Palmitoylation and Small Molecule Inhibitors
K. Mills, J. Misra, H. Torabifard·bioRxiv·Oct 24, 2023